News for hackers. Stuff that matters.

A comment on $6.96B was raised by private longevity companies in 2022. Parent comment

Re:$6.96B was raised by private longevity companies in 2022 by inglor_cz on Friday January 27, 2023 @03:16PM (#34551232)
So is the treatment something highly unusual?

I am sorry to be prying such information out of you, but things with such a cost label tend to be very high-tech (e.g. tumor-invading lymphocytes etc. that need to be cultivated for each patient separately, which cannot possibly be cheap).

[ Parent | on HN ]
Re:$6.96B was raised by private longevity companies in 2022 by ceejayoz on Friday January 27, 2023 @03:19PM (#34551277)
It's a monoclonal antibody.

I suspect it'll look cheap in comparison to life extension treatments.

[ Parent | on HN ]
Re:$6.96B was raised by private longevity companies in 2022 by jjk166 on Friday January 27, 2023 @04:52PM (#34552395)
That's because monoclonal antibodies are targeted to a very specific protein. Polyclonal antibodies which can be used more generally are much cheaper. You're paying for the purity, not the substance.
[ Parent | on HN ]